BIOMAT Database Logo BIOMAT Database Logo

Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. 1989

K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
2nd Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Seven anaemic patients with predialysis chronic renal failure were treated with human recombinant erythropoietin. Anaemia was improved, with a 31% increase in haematocrit, but blood pressure increased in all patients with an average of 12% in systolic (P less than 0.01), 14% in diastolic (P less than 0.05) and 13% in mean blood pressure (P less than 0.05). Blood volume was significantly increased by an average of 12%. Cardiac output increased in three of seven patients, and total peripheral resistance in four. GFR, RBF and RPF were not changed but filtration fraction increased significantly (P less than 0.05). It is suggested that blood pressure elevation might be developed as a result of volume expansion, elevated cardiac output, and increased total peripheral resistance.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.
November 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
January 1992, Przeglad lekarski,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
[Effect of recombinant human erythropoietin on renal function in predialysis patients].
June 1991, Nihon Jinzo Gakkai shi,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
[Anaemia treatment with recombinant human erythropoietin in predialysis patients with chronic renal failure--own experience].
October 2003, Polskie Archiwum Medycyny Wewnetrznej,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Study of the effect of recombinant erythropoietin on renal anaemia in predialysis patients with chronic renal failure.
January 1994, Folia medica,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
January 2005, Renal failure,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia.
January 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?
January 1990, Contributions to nephrology,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function.
January 1988, Contributions to nephrology,
K Onoyama, and H Kumagai, and K Takeda, and K Shimamatsu, and M Fujishima
Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
April 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!